PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	1.68TCr 1.12Cr 97.89L 90.29L 83.39L 1.58Cr 106.73Cr 1.61Cr 11Cr 4.24Cr 53Cr 4.2Cr 4.11Cr 180.75Cr	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	2.38TCr 1.59Cr 1.39Cr 1.28Cr 1.18Cr 2.24Cr 151.38Cr 2.28Cr 15Cr 6.01Cr 75Cr 5.96Cr 5.83Cr 256.38Cr	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/24/22	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/24/25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/24/21	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/24/16	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/23/26	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/23/21	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/23/15	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/23/31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/23/31	PCL to Raise 36 Billion Won via Share Issuance	MT
23/23/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/22/29	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	3,80,000
10 years	5,900	5,23,333.33

PCL, Inc. Share Price

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-86.10%	1.12Cr
VERACYTE, INC.	-3.93%	-0.19%	+110.38%	+101.31%	454.58Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-3.39%	-0.61%	+78.17%	+178.20%	337.05Cr
BGI GENOMICS CO., LTD.	+4.20%	-1.15%	-27.01%	-38.77%	204.99Cr
IOVANCE BIOTHERAPEUTICS, INC.	-3.20%	-1.86%	+126.20%	-46.25%	188.87Cr
CAREDX, INC.	-2.06%	-2.33%	+41.63%	+173.08%	147.28Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.01%	+0.83%	+123.08%	-51.36%	90Cr
SEEGENE, INC.	+6.42%	-1.19%	-10.08%	+42.16%	88Cr
CURIOX BIOSYSTEMS CO., LTD	+7.05%	+1.07%	-2.63%	-	49Cr
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.63%	-3.18%	-36.79%	-17.64%	48Cr
Average	+0.71%	-1.07%	+40.29%	+28.29%	160.87Cr
Weighted average by Cap.	-1.13%	-0.66%	+67.89%	+72.48%

	2023	2024
Net sales	842.95Cr 56.14L 49.1L 45.29L 41.83L 79.37L 54Cr 80.71L 5.41Cr 2.13Cr 26Cr 2.11Cr 2.06Cr 91Cr	124.62Cr 8L 7L 7L 6L 11.73L 7.92Cr 11.93L 80L 31.42L 3.9Cr 31.16L 30.48L 13Cr
Net income	-2.03TCr -1.35Cr -1.18Cr -1.09Cr -1.01Cr -1.91Cr -129.05Cr -1.95Cr -13Cr -5.12Cr -64Cr -5.08Cr -4.97Cr -218.55Cr	-5.23TCr -3.49Cr -3.05Cr -2.81Cr -2.6Cr -4.93Cr -332.43Cr -5.01Cr -34Cr -13Cr -163.77Cr -13Cr -13Cr -563Cr
Net Debt	720.41Cr 47.98L 41.97L 38.71L 35.75L 67.83L 46Cr 68.98L 4.62Cr 1.82Cr 23Cr 1.8Cr 1.76Cr 77Cr	703.02Cr 46.82L 40.95L 37.77L 34.89L 66.2L 45Cr 67.31L 4.51Cr 1.77Cr 22Cr 1.76Cr 1.72Cr 76Cr